|
Recent Developments |
|
01-JAN-19
Shilpa Medicare has received U.S. Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials. Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.
16-NOV-18
Shilpa Medicare has received tentative approval from USFDA for its ANDA for Dimethyl Fumarate Delayed Release Capsules 120 mg & 240 mg.
11-JU... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Dec-2015(9) | 31-Mar-2015 (12) | 31-Mar-2014 (12) | | Net sales | 4962.38 | 5654.02 | 5273.68 | | Other Income | 52.02 | 54.53 | 88.53 | | Total Income | 5014.40 | 5708.55 | 5362.21 | | Cost of goods sold | 3802.01 | 4288.74 | 4096.50 | | OPBDIT | 1212.39 | 1419.81 | 1265.71 | | PAT | 775.29 | 841.81 | 808.57 | | Gross Block | - | - | - | | Equity capital | 77.10 | 77.10 | 73.57 | | EPS (Rs.) | - | 21.94 | 21.98 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 15.50 - 48.27 | 6.19 - 19.25 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 24.2 | 24.9 | 23.6 | | Net margin (% of OI) | 15.5 | 14.7 | 15.1 |
|
|
Detailed Financials
|
|
|
|
|
